- Home
- BIIB vs HPE Comparison
BIIB vs HPE Comparison
Compare BIIB & HPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HPE
- Stock Information
- Founded
- BIIB 1978
- HPE 1939
- Country
- BIIB United States
- HPE United States
- Employees
- BIIB N/A
- HPE N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HPE Retail: Computer Software & Peripheral Equipment
- Sector
- BIIB Health Care
- HPE Technology
- Exchange
- BIIB Nasdaq
- HPE Nasdaq
- Market Cap
- BIIB 18.8B
- HPE 26.8B
- IPO Year
- BIIB 1991
- HPE N/A
- Fundamental
- Price
- BIIB $133.99
- HPE $20.79
- Analyst Decision
- BIIB Buy
- HPE Buy
- Analyst Count
- BIIB 27
- HPE 14
- Target Price
- BIIB $188.17
- HPE $22.67
- AVG Volume (30 Days)
- BIIB 1.3M
- HPE 21.3M
- Earning Date
- BIIB 07-31-2025
- HPE 09-03-2025
- Dividend Yield
- BIIB N/A
- HPE 2.51%
- EPS Growth
- BIIB 26.39
- HPE N/A
- EPS
- BIIB 10.12
- HPE 1.04
- Revenue
- BIIB $9,816,400,000.00
- HPE $31,649,000,000.00
- Revenue This Year
- BIIB N/A
- HPE $11.54
- Revenue Next Year
- BIIB N/A
- HPE $7.92
- P/E Ratio
- BIIB $13.29
- HPE $19.84
- Revenue Growth
- BIIB 1.59
- HPE 11.79
- 52 Week Low
- BIIB $110.04
- HPE $11.97
- 52 Week High
- BIIB $238.00
- HPE $24.66
- Technical
- Relative Strength Index (RSI)
- BIIB 56.84
- HPE 66.17
- Support Level
- BIIB $129.08
- HPE $20.55
- Resistance Level
- BIIB $137.84
- HPE $21.72
- Average True Range (ATR)
- BIIB 4.01
- HPE 0.54
- MACD
- BIIB 0.57
- HPE 0.13
- Stochastic Oscillator
- BIIB 70.81
- HPE 77.42
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About HPE Hewlett Packard Enterprise Company
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure. It uses a primarily outsourced manufacturing model and employs 60,000 people worldwide.